Jeffrey Cram
Vice President of Process Development, Elevatebio
Jeffrey Cram is listed as Vice President of Process Development, Elevatebio. Jeffrey is scheduled to speak at Advanced Therapies Week 2027 on 19 January 2027.
Compiled from published conference agendas; not yet confirmed by Jeffrey. Is this you? Claim this profile.
About
Jeff Cram is the Vice President of Process Development at ElevateBio, with expertise encompassing development, scale up, characterization, and manufacturing of cellular therapies, viral vector, and mRNA for clinical and commercial applications. His industry career spans over two decades and includes leadership roles at bluebird bio, where he contributed to the development and approval of pioneering cell and gene therapies such as Zynteglo®, Skysona®, Abecma®, and Lyfgenia®. Prior to bluebird, Jeff served as the Technical Project Leader in the CMCF, Novel Cell Therapy Laboratory at the Dana Farber Cancer Institute where he successfully developed, transferred and manufactured a wide variety of novel gene and cell therapy products. Jeff has built and led world-class cell and gene therapy process development teams over his career. His teams have focused on product and process understanding and worked to develop pioneering technologies that have been adopted throughout the industry. At Elev
Upcoming
Advanced Therapies Week 2027 19 January 2027 – 21 January 2027
- Session 1: Autologous and allogeneic cell therapies – what’s the latest progress in reducing process timeframes and cost of goods while enhancing scalability, quality, and consistency? Speaker · 19 January 2027
- Spotlight: From complex to cost-effective: De-risking cell therapy manufacturing with automation and in vivo capabilities Speaker · 19 January 2027
- Workshop: From cell selection to fill-finish: Building connected cell therapy manufacturing workflows Speaker · 20 January 2027
Spoke alongside
People who have shared a session with Jeffrey at events on B2DB.
- Amelia Heesen Field Application Specialist, Cell & Gene Therapy Technologies · Fresenius Kabi 1 shared session
- Greg Russotti Chief Technology & Manufacturing Officer · Century Therapeutics 1 shared session
- Isabel Tian Senior Director, Scientific Affairs · Cellares 1 shared session
- Mamta Kalra Vice President Process and Analytical Development · Immatics 1 shared session
- Nicholas Boyd Head of Biology, Applications & Validation · Celleo 1 shared session
- Sarah Yuan Chief Technology Officer · Cabaletta Bio 1 shared session